ICCC vs PH · rev $26.5M vs P/E 28, rev $19.85B
ImmuCell Corporation (ICCC) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
ICCC currently screens at market cap $58.9M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the ICCC and PH stock pages for the full models.
Not investment advice.